IL269409A - שילובי מעכבים chk1 ו-wee1 - Google Patents

שילובי מעכבים chk1 ו-wee1

Info

Publication number
IL269409A
IL269409A IL26940919A IL26940919A IL269409A IL 269409 A IL269409 A IL 269409A IL 26940919 A IL26940919 A IL 26940919A IL 26940919 A IL26940919 A IL 26940919A IL 269409 A IL269409 A IL 269409A
Authority
IL
Israel
Prior art keywords
wee1
chk1
inhibitors
combinations
Prior art date
Application number
IL26940919A
Other languages
English (en)
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of IL269409A publication Critical patent/IL269409A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL26940919A 2017-03-31 2019-09-17 שילובי מעכבים chk1 ו-wee1 IL269409A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762480101P 2017-03-31 2017-03-31
PCT/US2018/025464 WO2018183891A1 (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Publications (1)

Publication Number Publication Date
IL269409A true IL269409A (he) 2019-11-28

Family

ID=62002508

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26940919A IL269409A (he) 2017-03-31 2019-09-17 שילובי מעכבים chk1 ו-wee1

Country Status (11)

Country Link
US (1) US20200108074A1 (he)
EP (1) EP3600247A1 (he)
JP (1) JP2020512977A (he)
KR (1) KR20190130621A (he)
CN (1) CN110678169A (he)
AU (1) AU2018243667A1 (he)
CA (1) CA3058457A1 (he)
IL (1) IL269409A (he)
MX (1) MX2019011506A (he)
SG (1) SG11201908788YA (he)
WO (1) WO2018183891A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
BR112021019703A2 (pt) 2019-04-09 2021-12-14 Nuvation Bio Inc Compostos heterocíclicos e usos dos mesmos
KR20220088896A (ko) * 2019-10-25 2022-06-28 아스트라제네카 아베 암을 치료하는 방법
EP4115907A1 (en) * 2020-02-27 2023-01-11 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
CN115778962A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 治疗男性食管癌患者的药物及其相关应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
JPH07507768A (ja) 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003010444A1 (en) 2001-07-23 2003-02-06 Shock-Proof Solutions Pty Ltd Mechanical shock absorbing apparatus
JP2006528661A (ja) 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050176733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US7560462B2 (en) 2004-07-02 2009-07-14 Icos Corporation Compounds useful for inhibiting CHK1
CN101115727A (zh) 2004-08-19 2008-01-30 艾科斯有限公司 用于抑制chk1的化合物
SI1869020T1 (sl) * 2005-03-29 2011-02-28 Icos Corp Derivati heteroaril uree, ki so uporabni za inhibicijo chk1
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US20100113445A1 (en) 2007-03-20 2010-05-06 Smithkline Beecham Corporation Chemical Compounds
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
AU2010218781A1 (en) 2009-02-25 2011-07-28 Msd K.K. Pyrimidopyrimidoindazole derivative
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP2640386B1 (en) * 2010-11-16 2017-01-18 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
EP2855448B1 (en) * 2012-05-15 2017-02-08 Cancer Research Technology Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017216559A1 (en) 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2018243667A1 (en) 2019-10-17
CA3058457A1 (en) 2018-10-04
US20200108074A1 (en) 2020-04-09
CN110678169A (zh) 2020-01-10
JP2020512977A (ja) 2020-04-30
SG11201908788YA (en) 2019-10-30
KR20190130621A (ko) 2019-11-22
WO2018183891A1 (en) 2018-10-04
MX2019011506A (es) 2019-11-01
EP3600247A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
DK3606954T3 (en) Anti-LAG3-antistoffer
DK3734167T3 (en) Airconditionsystem
IL257026A (he) צורות מוצקות של אלוקסדולין
IL269409A (he) שילובי מעכבים chk1 ו-wee1
DK3499914T3 (en) Høreapparatsystem
DK3700925T3 (en) Hidtil ukendt t-cellereceptor
IL274627A (he) צורות מוצקות של ואלבנאזין
IL265628A (he) צורות מוצקות של ואלבנאזין
AU201714106S (en) Mandoline
ZA201706282B (en) Solid forms of menaquinols
DK3401557T3 (en) Træskrue
DK3485765T3 (en) Computerbord
DK3630041T3 (en) Stimulationsapparat
DK3718525T3 (en) Motoriseret asssistancesystem
DK3704866T3 (en) Datatransmissionssystem
GB201704620D0 (en) Combinations
GB201700825D0 (en) Poliovaccine
IL254666A0 (he) צורות גבישיות של אלדקלציטול
GB201721386D0 (en) Chrondogy of time-wave
DK3425793T3 (en) Tagsystem
DK3618761T3 (en) Intrakorporalt perfusionssystem
DK3351149T3 (en) Syltetøjsfontæne
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure
GB201715756D0 (en) Disclosure